Publicaciones (39) Publicaciones de BEATRIZ ARRIZABALAGA AMUCHASTEGUI

2021

  1. Acquired thrombotic thrombocytopenic Purpura diagnosed during first trimester of pregnancy with excellent outcome after plasma exchange and rituximab, a case report

    Clinical Case Reports, Vol. 9, Núm. 3, pp. 1304-1306

  2. Prediction of liver iron overload in the Basque country (Spain) in patients referred for hyperferritinemia

    Digestive and Liver Disease

2020

  1. Autoimmune haemolytic anaemias: A retrospective study of 93 patients

    Medicina Clinica, Vol. 154, Núm. 9, pp. 331-337

  2. Body mass index and alcohol consumption are directly related with liver steatosis. Results from a prospective study of patients referred for hyperferritinemia

    Annals of Hepatology

  3. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671

  4. Liver iron concentration in dysmetabolic hyperferritinemia: Results from a prospective cohort of 276 patients

    Annals of Hepatology, Vol. 19, Núm. 1, pp. 31-35

  5. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151

  6. Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies

    Journal of Medical Genetics, Vol. 57, Núm. 4, pp. 258-268

  7. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2017

  1. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

  3. Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload

    Clinical Biochemistry, Vol. 50, Núm. 16-17, pp. 911-917

  4. Phenotype of mutations in the promoter region of the β-globin gene

    Journal of Clinical Pathology, Vol. 70, Núm. 10, pp. 874-878

  5. Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry

    Annals of Hematology, Vol. 96, Núm. 10, pp. 1727-1733

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Detection of new pathogenic mutations in patients with congenital haemolytic anaemia using next-generation sequencing

    International Journal of Laboratory Hematology, Vol. 38, Núm. 6, pp. 629-638

  3. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

  4. Hereditary xerocytosis, a misleading anemia

    Annals of Hematology

  5. Severe neonatal jaundice due to a de novo glucose-6-phosphate dehydrogenase deficient mutation

    International Journal of Laboratory Hematology

  6. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

    Medicina Clinica